About Jon

Jon focuses on developing and executing worldwide patent strategies for life sciences and pharmaceutical companies. He counsels clients on drug design, life cycle extension strategies, clinical trial inventions and Orange Book listing strategies. Notable patent portfolios Jon has worked on include Epidiolex, Copiktra, Farydak, Arikayce, Amrix, Lamictal and Evekeo ODT, as well as numerous candidates in clinical trials.

He has counselled clients in small molecule and peptide drug discovery programs, polymorphs, pharmaceutical formulations, 505(b)(2) strategies, natural products, clinical trial inventions, companion diagnostics, biomaterials, biotechnologies and manufacturing processes.

Jon has significant experience conducting patentability, invalidity, freedom-to-operate and noninfringement analyses, along with conducting due diligence for early-, mid- and late-stage fundraisings, public offerings, acquisitions and dispositions.  

Speaking engagements

Education

Montana State University
PhD, Organic Chemistry, 2015

Ohio Northern University
JD, 2010

University of Georgia
BS, Environmental Resource Science, 2007

University of Georgia
BS, Chemistry, 2006

Rankings and accolades

Best Lawyers: Ones to Watch – Patent and IP, 2024

Concurrences: Readers’ Choice Antitrust Writing Award for Intellectual Property, 2024

The Legal 500 US: Recommended Lawyer in Patents: prosecution (including re-examination and post-grant proceedings), 2021

Memberships and affiliations

American Intellectual Property Law Association